SEC-sourced researchBeta
CASIF
CASI Pharmaceuticals, Inc.
Company comparison ↗
Data passport
- CIK
- 0001962738
- Exchange
- OTC
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 2, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 33,879,000.0000 | May 15, 2026 |
| December 2024 | 28,537,000.0000 | May 15, 2026 |
| December 2025 | 20,712,000.0000 | May 15, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 20,712,000.0000 | -48,058,000.0000 | -20,754,000.0000 | 25,650,000.0000 | 62,932,000.0000 | May 15, 2026 |
| December 2024 | 28,537,000.0000 | -39,258,000.0000 | -29,224,000.0000 | 53,674,000.0000 | 51,823,000.0000 | May 15, 2026 |
| December 2023 | 33,879,000.0000 | -26,960,000.0000 | -19,967,000.0000 | — | — | May 15, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $20.71M | December 2025 | May 15, 2026 | 20-F |
| Previous period revenueRevenues | $28.54M | December 2024 | May 15, 2026 | 20-F |
| Net incomeNetIncomeLoss | -$48.06M | December 2025 | May 15, 2026 | 20-F |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$20.75M | December 2025 | May 15, 2026 | 20-F |
| Total assetsAssets | $25.65M | December 2025 | May 15, 2026 | 20-F |
| Total liabilitiesLiabilities | $62.93M | December 2025 | May 15, 2026 | 20-F |